-
Skye Bioscience Is Pursuing A New Kind Of Glaucoma Drug
Tuesday, February 23, 2021 - 9:02am | 1030Read More...The following article is sponsored by Skye Bioscience, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. The beginning of 2021 marked the start of a busy...
-
Benzinga Cannabis Hour Recap: Skye Bioscience CEO Discusses How Cannabinoids May Treat Glaucoma
Thursday, February 11, 2021 - 2:31pm | 527Read More...Cannabinoid receptors distributed within the body are part of the endocannabinoid system that largely affects processes such as mood, memory, pain-sensation, and appetite, to name a few. Two types of receptors — CB1 and CB2 — “play a vital role in managing different body...
-
Emerald Bioscience Creates Unique Path to Prevent Blindness Using Patented Synthetic Cannabinoids
Friday, December 4, 2020 - 10:17pm | 1131Read More...The following article is sponsored by Emerald Bioscience Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. The rapid innovation and growth in biotechnology is being...
-
Stifel's Doctor Survey Triggers Glaukos Downgrade
Friday, April 13, 2018 - 8:27am | 364Read More...The bullish case for Glaukos Corp (NYSE: GKOS), a company focusing on designing products and procedures for the treatment of glaucoma, is based on expectations the company will stabilize its micro-invasive glaucoma surgery concomitant market share in 2019. But after speaking with dozens of doctors...
-
Glaukos Way Ahead Of The Glaucoma Competition
Friday, September 23, 2016 - 12:53pm | 424Read More...Cantor Fitzgerald reiterated its Buy rating and $41 price target on Glaukos Corp (NYSE: GKOS) after the company reported efficacy data from a three-year international study of two iStent devices in over 100 devices. Elaborating on the trial and results, the firm's analyst Elemer Piros noted that...
-
Does Clearside Biomedical Have 91% Upside?
Monday, June 27, 2016 - 9:10am | 404Read More...Shares of Clearside Biomedical Inc (NASDAQ: CLSD) has 91 percent upside, according to a note from Stifel, which initiated coverage of the stock with a Buy rating and $13 price target. "Clearside has developed a novel ocular injection platform to deliver drug[s] optimally throughout the eye by way...
-
Glaukos: What Data Points Really Matter?
Friday, April 22, 2016 - 3:50pm | 277Read More...Piper Jaffray said it values Glaukos Corp (NYSE: GKOS)'s suprachoroidal stent in development at $175 million based on Alcon's announcement that it paid $352 million for Glaukos competitor, Transcend, which also has a similar product. Analyst Matt O'Brien said Transcend's CyPass...
-
Aerie Pharmaceuticals Announces Initiation Of Second Phase 3 Trial For Roclatan
Monday, March 28, 2016 - 8:05am | 275Read More...Aerie Pharmaceuticals Inc (NASDAQ: AERI), a clinical-stage pharmaceutical company that focuses on the treatment of glaucoma and other diseases of the eye, announced on Monday that it has successfully began dosing the first patients enrolled in Mercury 2, the company's second Phase 3 registration...
-
Good News from Aerie Pharma; Aratana Therapeutics Should Cheer Investors
Thursday, February 18, 2016 - 10:08am | 496Read More...Aerie Pharmaceuticals Inc (NASDAQ: AERI) and Aratana Therapeutics Inc (NASDAQ: PETX) have come out with positive announcements that should cheer investors on Thursday. Aerie Pharma reported the successful 12-month interim safety results of Rocket 2, Aerie's second Phase 3 registration trial for...
-
Glaukos Brings New Hope To Those Suffering From Glaucoma
Wednesday, June 24, 2015 - 3:09pm | 881Read More...Glaukos Corp (NYSE: GKOS), a glaucoma medical device maker, hopes to raise $89 million in its upcoming IPO on Thursday. Glaukos will offer 6 million shares between $16 and $17 per share. The company will list on the NYSE under the ticker GKOS. At the midpoint of the offering, Glaukos market cap...
-
IPO Outlook: Inotek's Vision For The Future
Wednesday, February 4, 2015 - 2:28pm | 1080Read More...Inotek Pharmaceuticals Corp (NASDAQ: ITEK), founded in 1999, is a clinical-stage biopharmaceutical company centered on the discovery, development and commercialization of therapies to treat glaucoma. Glaucoma is condition where the eye is unable to properly drain fluid, which leads to a buildup...
